help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by O'Keane, V.
Right arrow Articles by Dinan, T. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by O'Keane, V.
Right arrow Articles by Dinan, T. G.

Journal of Clinical Endocrinology & Metabolism, Vol 75, 11-14, Copyright © 1992 by Endocrine Society

ARTICLES

Sex steroid priming effects on growth hormone response to pyridostigmine throughout the menstrual cycle

V O'Keane and TG Dinan
Department of Psychiatry, Trinity College Medical School, St. James's Hospital, Dublin, Ireland.

To explore the effect of estradiol and progesterone on the GH response to the indirect cholinergic agonist pyridostigmine nine healthy women were challenged with both active drug and placebo at three time points in two consecutive menstrual cycles: a total of six neuroendocrine tests. A randomized, double-blind, counterbalanced design was used. Subjects were tested in the early follicular, mid-cycle, and luteal phases of the cycle. A cannula was inserted in a forearm vein after an overnight fast and baseline GH, estradiol, and progesterone samples were drawn. After 120 mg oral pyridostigmine or placebo tablets further blood samples for GH analysis were drawn at intervals over 3 h. When expressed as maximum change from baseline (delta GH) mean GH responses to pyridostigmine increased incrementally from early (8.4 +/- 2.7 micrograms/L) through mid (18 +/- 1.3 micrograms/L) to late (22.2 +/- 1.9 micrograms/L) cycle. This represents a significant effect of cycle phase on the GH response to pyridostigmine (P less than 0.001, as assessed by analysis of variance). Responses to placebo did not vary. Plasma estradiol values were significantly correlated with GH responsivity to active drug throughout the cycle (P less than 0.02). Multiple regression analysis also revealed a significant positive correlation between progesterone levels and GH response to pyridostigmine (P less than 0.02). Estrogens augment GH responses to other challenges but a priming effect of progesterone on GH responsivity has not previously been demonstrated. Various mechanisms are discussed including a possible sex steroid priming effect on acetylcholine neurotransmission.


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
X.-D. Qu, I. T. Gaw Gonzalo, M. Y. Al Sayed, P. Cohan, P. D. Christenson, R. S. Swerdloff, D. F. Kelly, and C. Wang
Influence of Body Mass Index and Gender on Growth Hormone (GH) Responses to GH-Releasing Hormone Plus Arginine and Insulin Tolerance Tests
J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1563 - 1569.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
W J Cutter, R Norbury, and D G M Murphy
Oestrogen, brain function, and neuropsychiatric disorders
J. Neurol. Neurosurg. Psychiatry, July 1, 2003; 74(7): 837 - 840.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1992 by The Endocrine Society